Inflammatory markers, the tryptophan-kynurenine pathway, and vitamin B status after bariatric surgery

Monika H. E. Christensen¹,², Dag J. Fadnes³, Therese H. Røst⁴, Eva R. Pedersen¹,⁴, John R. Andersen⁵,⁶, Villy Våge⁶,⁷, Arve Ulvik⁸, Øivind Midttun⁹, Per M. Ueland¹,⁹, Øivind Nygård⁴,¹⁰, Gunnar Mellgren¹⁰,¹¹*

¹ Department of Clinical Science, University of Bergen, Bergen, Norway, ² Department of Medicine, Haukeland University Hospital, Bergen, Norway, ³ Medical Department, Førde Hospital Trust, Førde, Norway, ⁴ Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, ⁵ Sogn og Fjordane University College, Førde, Norway, ⁶ Center of Health Research, Førde Hospital Trust, Førde, Norway, ⁷ Department of Surgery, Voss Hospital, Bergen Health Trust, Voss, Norway, ⁸ Bevital AS, Bergen, Norway, ⁹ Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway, ¹⁰ KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹¹ Hormone Laboratory, Haukeland University Hospital, Bergen, Norway

*gunnar.mellgren@med.uib.no

Abstract

Objective

Obesity is associated with increased inflammation and insulin resistance. In conditions with chronic immune activation, low plasma vitamin B6-levels are described, as well as an increased kynurenine:tryptophan-ratio (KTR). We investigated circulating tryptophan, kynurenine and its metabolites, neopterin, B-vitamins, CRP, and HbA1c in individuals with obesity before and after bariatric surgery.

Methods

This longitudinal study included 37 patients with severe obesity, scheduled for bariatric surgery. Blood samples were taken at inclusion and at three months and one year postoperatively.

Results

We observed significant positive correlations between HbA1c and both 3-hydroxy-kynurenine and 3-hydroxyanthranilic acid at inclusion. After surgery, fasting glucose, HbA1C and triglycerides decreased, whereas HDL-cholesterol increased. Tryptophan, kynurenine and its metabolites, except for anthranilic acid, decreased during weight loss. The KTR and CRP decreased while vitamin B6 increased during the year following operation, indicating reduced inflammation (all p<0.05).

Conclusions

In patients with obesity subjected to bariatric surgery, levels of 3-hydroxykynurenine and 3-hydroxyanthranilic acid seemed to be positively correlated to impaired glucose tolerance.
One year following surgery, plasma levels of the kynurenine metabolites were substantially decreased, along with a metabolic improvement. The relation of circulating kynurenine pathway metabolites with biomarkers of metabolic impairment in patients with obesity needs further evaluation.

Introduction

Severe obesity is associated with highly elevated risk of adverse health outcomes [1] including type 2 diabetes (T2D), hypertension, dyslipidaemia, and cardiovascular diseases, as well as premature death and several forms of cancers [2]. Weight loss reduces existing co-morbidities in patients with obesity and may cause remission of T2D [3]. Compared to lifestyle intervention and pharmacological treatment, bariatric surgery leads to greater weight loss and metabolic improvement in patients with severe obesity [4].

Adipose tissue has important endocrine functions regulating energy homeostasis, insulin sensitivity, lipid and carbohydrate metabolism [5, 6]. In obesity, an increased number of pro-inflammatory immune response cells are found in adipose tissue. Consequently, increased levels of pro-inflammatory cytokines are found [7–9]. Inflammation in adipose tissue seems to promote and accentuate insulin resistance, an early feature in the progression from normoglycemia to overt T2D [10].

The essential amino acid tryptophan is obtained from the diet. Tryptophan is mainly metabolised through the kynurenine pathway and is a source for NAD+, an essential cofactor in energy metabolism. A smaller portion of tryptophan is used to synthesize the neurotransmitters serotonin and melatonin (Fig 1)[11]. In the liver tryptophan is metabolized by the enzyme tryptophan 2,3 dioxygenase (TDO), induced by stress and steroids. Plasma levels of kynurenine, however, might be more closely linked to the activity of the inflammation-induced enzyme indoleamine 2,3-dioxygenase (IDO) [12]. IDO is ubiquitously expressed and induced by inflammatory cytokines such as IFN-γ [13]. The ratio between circulating kynurenine and tryptophan (KTR) in plasma is thus often used as a measure of IFN-γ activation. Neopterin, which is released in large quantities by activated macrophages, is another well-established marker of IFN-γ activity [14, 15]. Kynurenine metabolites have distinct roles in immune-regulation or can be neuroactive [16, 17]. Several key enzymes in the tryptophan-kynurenine metabolic pathway require pyridoxal 5’-phosphate (PLP, vitamin B6) or flavin adenine dinucleotide (FAD, vitamin B2) as cofactors (Fig 1). PLP is the most commonly used serum marker of vitamin B6 status and reflects the body store of this vitamin [18]. In conditions associated with chronic inflammation low plasma levels of PLP have been described [19].

Obesity leads to low-grade chronic inflammation and is associated with increased risk of metabolic diseases. Inflammatory markers may be useful as a diagnostic tool to identify subjects with obesity at high risk of developing metabolic diseases. In this study we present a tryptophan-kynurenine metabolite profile in plasma samples of patients with morbid obesity at baseline, 3 and 12 months after bariatric surgery.

Materials and methods

Participants

The study includes 37 subjects undergoing bariatric surgery, either laparoscopic sleeve gastrectomy (LSG) or biliopancreatic diversion with duodenal switch (BPD-DS), at the Department
of Surgery at Førde Hospital, Norway. A total of 40 subjects were recruited to the study, but three patients withdrew from surgery. LSG was performed by resecting along a size 32 French tube from the pylorus to the cardia creating a gastric volume of 100 ml or less. BPD-DS was performed by creating a slightly greater gastric tube, excluding 60% of the small bowel and making a common channel of 10% of the small bowel length. Further details on the surgical procedures can be found in previous publications [20, 21]. Criteria to be scheduled for bariatric surgery were age 18–60 years, BMI \( \geq 40 \text{ kg/m}^2 \) or \( \geq 35.0 \text{ kg/m}^2 \) if at least one obesity-related comorbidity (such as T2D, hypertension or dyslipidaemia) was present. T2D was diagnosed if fasting plasma glucose was \( \geq 7.0 \text{ mmol/L} \) and/or plasma glucose measured 2 hours after intake of 75g of glucose was \( \geq 11.1 \text{ mmol/L} \). Eligibility criteria also included no alcohol or drug abuse and no major psychiatric disorder. Participants were recruited during the period from September 2010 to May 2012. In general, patients who had T2D treated with insulin, were using two or more antihypertensive drugs and/or received lipid-lowering treatment were scheduled for BPD-DS. Inclusion and exclusion criteria for taking part in the study were identical to the indications for bariatric surgery. None of the patients dropped out of the study.

Fig 1. The kynurenine pathway of tryptophan metabolism. IDO, indoleamine 2,3-dioxygenase; TDO, tryptophan 2,3-dioxygenase; KAT, kynurenine aminotransaminase; KMO, kynurenine 3-monooxygenase; KYNU, kynureninase; 3OH-kynurenine, 3-hydroxy kynurenine; 3OH-anthranilic acid, 3-hydroxy anthranilic acid; B6, vitamin B6 (pyridoxal 5'-phosphate); B2, vitamin B2 (flavin adenine dinucleotide).

https://doi.org/10.1371/journal.pone.0192169.g001
Thus, any missing data is due to patients not being able to attend follow-up appointments for personal reasons or random errors in the data collection. All patients were alive at the end of the study.

Clinical examination and blood sampling were performed two days before surgery and repeated after 3 and 12 months. Weight was measured to the nearest 0.1 kilograms on electronic scales with participants dressed in light clothing, and height in standing position without shoes was measured to the nearest millimetre. Body mass index (BMI) was calculated as weight divided by the square of body length (kg/m$^2$). Percentage excess body mass index loss (%EBMIL) from baseline to the one-year follow-up was calculated using the formula 100 - ((Follow-up BMI - 25)/(Beginning BMI - 25))x100.

At inclusion 10 out of 37 patients used multivitamin supplements. Following surgery, all patients were instructed to take one multivitamin supplement daily. The subset undergoing BPD-DS were also instructed to take 30,000 IE of 25(OH)D and 2 gram calcium carbonate per day. At 3 months after surgery 28 patients reported the use of multivitamin supplements, containing a daily dose of 1.6–1.7 mg of vitamin B2 (riboflavin), 18–20 mg vitamin B3 (niacin), and 1.2–2.0 mg vitamin B6 (pyridoxine), in addition to other vitamins and minerals. After 12 months 32 patients used supplements.

The study was approved by the Western Norway Regional Committee for Medical Research Ethics (ref.nr. 2009/2174). All enrolled subjects provided informed written consent, and the study was performed according to the principles of the Declaration of Helsinki.

**Biochemical analyses**

All blood samples were drawn after a fasting period of at least twelve hours. Glucose, HbA1c, CRP, total cholesterol, HDL-cholesterol, and triglycerides were measured immediately at the Laboratory of Clinical Chemistry at Forde Hospital, using the Architect system from Abbot Diagnostics (North Chicago, Illinois, USA). Samples stored in the biobank were frozen within 60 minutes and kept at -20°C for 1–2 days before being stored at −80°C.

Plasma concentrations of tryptophan, kynurenine, kynurenic acid, anthranilic acid, 3-hydroxykynurenine, xanthurenic acid, 3-hydroxyanthranilic acid, quinolinic acid, neopterin, pyridoxal 5’-phosphate (PLP), riboflavin, nicotinamide N$^1$-methylnicotinamide, and creatinine were analysed by liquid chromatography/tandem mass spectrometry (LC-MS/MS) [22] at Bevital A/S, Bergen, Norway (www.bevital.no) by laboratory personnel blinded to the clinical characteristics and identity of the patients. Estimated glomerular filtration rate (eGFR) was calculated according to the Modification of Diet in Renal Disease (MDRD) Study Group formula [23].

**Statistical analysis**

Continuous variables are reported as median (25th-75th percentiles) and categorical variables as numbers (percentages). Where distributional assumptions were violated, measures were either log10 transformed (kynurenic acid, anthranilic acid, 3-hydroxykynurenine, xanthurenic acid, 3-hydroxyanthranilic acid, quinolinic acid, pyridoxal 5’-phosphate, riboflavin and N$^1$-methylnicotinamide) or ranked (CRP) before used in parametrical tests. To assess changes in baseline characteristics between inclusion and one year after surgery Friedman’s test was used. Changes over time between repeated end-point measures were assessed with a random intercept mixed model, adjusted for operation method and multivitamin supplement use. Correlations among continuous variables were assessed by Spearman rank correlation, corrected for age, gender and eGFR, as well as operation method when analysing correlations between changes over time. All tests were two-sided and p-values < 0.05 were considered to
be statistically significant. Statistical analyses were performed using SPSS statistics 22 for Mac (IBM Corporation, New York, NY, USA).

**Results**

**Baseline characteristics**

Median age (25th-75th percentile) of the 37 participants was 48 (42.5–53.5) years, 25 (68%) participants were females, and median BMI (25th-75th percentile) was 43.8 (40.9–47.6) kg/m². At inclusion 38% had diabetes, of which one patient had type 1 diabetes mellitus, 17% hypertension and 12% hypercholesterolemia. LSG was performed on 25 patients (68%) whereas 12 underwent BPD-DS (Table 1). For two of the participants EDTA-plasma samples at baseline were missing, though there were blood samples of these patients at three months and one year after surgery.

Patients selected for BPD-DS were older than the LSG patients and more frequently used anti-diabetic drugs. This subset also had higher levels of HbA1c, tryptophan and 3-hydroxyanthranilic acid. No other statistically significant differences in baseline characteristics according to bariatric surgical procedures were observed (Table 2).

**Correlations at baseline**

Correlations of plasma kynurenines, related inflammation markers and B vitamins with fasting glucose, HbA1c, TG:HDL-ratio at baseline, adjusted for age, gender and eGFR, are shown in Fig 2. None of the kynurenines were correlated to fasting glucose, whereas neopterin was strongly, positively correlated to both fasting glucose and HbA1c. Both 3-hydroxykynurenine and 3-hydroxyanthranilic acid showed strong positive associations to HbA1c, whereas

| Table 1. Baseline characteristics of the study population according to bariatric surgical procedures. |
|--------------------------------------------------|---------------------------------|---------------------------------|-----------------|-----------------|
| **All patients** & **(n = 37)** & **LSG** & **(n = 25)** & **BPD-DS** & **(n = 12)** & **p-value** |
| **Females (%)*** & 25 & 18 & 7 & 0.41 |
| **Age (years)** & 48.0 (42.5–53.5) & 44.0 (39.5–51.5) & 52.5 (48.3–58.5) & 0.011 |
| **BMI (kg/m²)** & 43.8 (40.9–47.6) & 45.4 (41.5–47.6) & 41.9 (38.3–51.0) & 0.98 |
| **Smoking (%)** & 14 (38%) & 9 (36%) & 5 (41%) & 0.74 |
| **Fasting glucose (mmol/L)** & 5.80 (5.30–8.63) & 5.50 (4.95–6.30) & 8.40 (5.93–15.6) & 0.066 |
| **HbA1C (%)** & 5.60 (5.50–6.90) & 5.60 (5.30–6.10) & 7.15 (5.68–10.4) & 0.003 |
| **Cholesterol (mmol/L)** & 4.90 (4.00–5.55) & 4.75 (3.93–5.83) & 4.90 (4.20–5.25) & 0.684 |
| **Triglycerides (mmol/L)** & 1.44 (1.25–1.77) & 1.43 (1.24–1.65) & 1.49 (1.22–2.21) & 0.286 |
| **HDL-Cholesterol (mmol/L)** & 1.06 (1.00–1.20) & 1.10 (1.00–1.28) & 1.00 (0.90–1.20) & 0.101 |
| **Creatinine (umol/L)** & 68.6 (59.1–76.0) & 68.8 (59.2–74.7) & 64.1 (58.5–82.7) & 0.506 |
| **eGFR (mL min⁻¹ per 1.73m²)** & 94.3 (80.1–106) & 94.2 (80.8–106) & 97.1 (73.0–108) & 0.140 |
| **Diabetes** & 13 (38%) & 6 (24%) & 7 (67%) & 0.041 |
| **Diabetes medication** & 10 (30%) & 3 (12%) & 7 (67%) & 0.003 |
| **Hypertension** & 17 (46%) & 11 (44%) & 6 (50%) & 0.73 |
| **Hypercholesterolemia** & 12 (32%) & 6 (24%) & 6 (50%) & 0.11 |

Values are given as median (25th to 75th percentile), or numbers (percentages). LSG, laparoscopic sleeve gastrectomy; BPD-DS, biliopancreatic diversion with duodenal switch; BMI, body mass index; eGFR, estimated glomerular filtration rate; Diabetes medication, if patients used oral antidiabetic drugs or insulin; Hypertension, if using one or more antihypertensive drugs; Hypercholesterolemia, using lipid lowering medication. p-values are based on Anova, adjusted for age, gender and BMI.

*P-values are based on chi square test
**P-values are based on students t-test

https://doi.org/10.1371/journal.pone.0192169.t001
3-hydroxykynurenine was also correlated positively to the TG:HDL-ratio. PLP was negatively correlated to glucose and HbA1c. At inclusion, BMI was positively correlated to CRP \( (p < 0.05) \), but we did not find correlations to any of the other markers measured in the study.

**Changes in clinical and metabolic baseline characteristics after bariatric surgery**

As expected, patients had significant weight loss after surgery. In the whole group %EBMIL was 89%. Reduction of body weight was higher in the BPD-DS group (%EBMIL 109% (85.7–114)) than in the LSG group (%EBMIL 84.7% (70.0–91.4), \( p < 0.005 \)). Fasting glucose (17%), HbA1c (13%), and triglycerides (39%) decreased while HDL-cholesterol (23%) increased, indicating a more favourable metabolic profile one year after surgery.

Before surgery 13 patients were diagnosed with diabetes, 10 of these used oral anti-diabetic drugs or insulin. After surgery none of the patients with T2D used insulin and only one patient used oral anti-diabetic medication (Table 3).

**Kynurenine pathway metabolites and inflammatory markers after bariatric surgery**

Circulating levels of metabolites in the kynurenine pathway of tryptophan metabolism at baseline, 3 and 12 months after surgery are given in Table 4. We observed decreased plasma levels of tryptophan and all the kynurenine pathway metabolites, except for anthranilic acid. These changes were generally apparent within the first three months after surgery. In contrast, anthranilic acid was unchanged at three months, but significantly increased after one year. The KTR and CRP decreased after surgery, while levels of neopterin were unchanged (Fig 3).
CRP was significantly reduced already three months after surgery and continued decreasing one year post-operatively, while the KTR was unchanged at three months but reduced after one year. Analysing the LSG and BPD-DS groups separately showed the same results as in the combined group regarding CRP, neopterin, and the B vitamins measured, as well as the kynurenine metabolites, except for anthranilic acid, which was increased in the BPD-DS group but not significantly changed in the LSG group.

**Fig 2.** Correlations of fasting glucose, HbA1c and the triglyceride:HDL ratio with tryptophan, kynurenine and the kynurenine metabolites, inflammatory markers, vitamin B6 and vitamin B3 at baseline. Regression coefficient based on Spearman rank correlation test, corrected for age, gender and eGFR, are shown in the figure. Tg, triglyceride; HDL, high density lipoprotein; Trp, tryptophan; Kyn, kynurenine; KA, kynurenic acid; AA, anthranilic acid; HK, 3-hydroxy kynurenine; XA, xanthurenic acid; HAA, 3-hydroxy anthranilic acid; QA, quinolinic acid; KTR, kynureninetryptophan ratio; PLP, pyridoxal 5’-phosphate. *p-value < 0.05; **p-value < 0.005.

https://doi.org/10.1371/journal.pone.0192169.g002

CRP was significantly reduced already three months after surgery and continued decreasing one year post-operatively, while the KTR was unchanged at three months but reduced after one year. Analysing the LSG and BPD-DS groups separately showed the same results as in the combined group regarding CRP, neopterin, and the B vitamins measured, as well as the kynurenine metabolites, except for anthranilic acid, which was increased in the BPD-DS group but not significantly changed in the LSG group.
Levels of PLP were not significantly changed at three months after surgery, but an increase was observed after one year. The vitamin B3 form nicotinamide as well as the catabolite N1-methylnicotinamide decreased three month after surgery, though the latter increased between three months and one year. Levels of N1-methylnicotinamide at one year post surgery did not

Table 3. Patient characteristics at inclusion and after bariatric surgery.

|                      | Inclusion (n = 37) | 12 months after surgery (n = 34) | p-value |
|----------------------|-------------------|---------------------------------|---------|
| Gender (% females)   | 25 (68%)          |                                 |         |
| Age (years)          | 47.1 (42.5–53.5)  |                                 |         |
| Smoking (%)          | 14 (38%)          | 10 (29%)                        | 0.56    |
| BMI (kg/m²)          | 43.8 (40.9–47.6)  | 27.1 (24.5–30.6)                | < 0.001 |
| Glucose (mmol/L)     | 5.80 (5.30–8.63)  | 4.80 (4.60–5.30)                | < 0.001 |
| HbA1C (%)            | 5.60 (5.50–6.90)  | 4.90 (4.50–5.20)                | < 0.001 |
| Cholesterol (mmol/L) | 4.90 (4.00–5.55)  | 4.45 (3.78–5.52)                | 0.086   |
| Triglycerides (mmol/L)| 1.44 (1.25–1.77)  | 0.88 (0.70–1.07)                | < 0.001 |
| HDL-cholesterol (mmol/L)| 1.06 (1.00–1.20) | 1.30 (1.08–1.50)               | 0.002   |
| Creatinine (umol/L)  | 68.6 (59.1–76.0)  | 63.6 (56.1–69.8)                | 0.003   |
| eGFR (mL min⁻¹per 1.73m²)| 94.3 (80.1–106)   | 107 (85.0–123)                 | 0.003   |
| Diabetes             | 13 (38%)          | 2 (5%)                          | < 0.001 |
| Diabetes medication  | 10 (30%)          | 2 (5%)                          | 0.002   |
| Hypertension         | 17 (46%)          | 5 (14%)                         | < 0.001 |
| Hypercholesterolemia | 12 (32%)          | 2 (5%)                          | 0.001   |

Values are given as median (25th to 75th percentile) or numbers (percentages). BMI, body-mass index; eGFR, estimated glomerular filtration rate; diabetes medication, if patients used per oral antidiabetic drugs or insulin; hypertension, if patients used one or more antihypertensive drugs; hypercholesterolemia, using lipid lowering medication. P-values are based on Friedman’s Two.

https://doi.org/10.1371/journal.pone.0192169.t003

Table 4. Circulating levels of tryptophan, kynurenines and B vitamins before and after bariatric surgery.

|                      | Inclusion (n = 35) | Time after surgery (months) | p-value |
|----------------------|-------------------|-----------------------------|---------|
|                      |                   | 3                           | 12      |
| Tryptophan and kynurenines |                 |                             |         |
| Tryptophan (µmol/L)  | 65.0 (60.1–73.4)  | 48.5 (41.6–54.7)            | 51.9 (43.8–60.3) | < 0.001 |
| Kynurenine (µmol/L)  | 1.68 (1.38–1.91)  | 1.22 (1.06–1.33)            | 1.23 (1.02–1.33) | < 0.001 |
| Kynurenic acid (nmol/L)| 58.7 (49.3–71.0) | 29.2 (23.5–33.6)            | 30.0 (22.6–42.6) | < 0.001 |
| Anthranilic acid (nmol/L)| 16.7 (13.5–20.0)| 16.0 (13.7–22.8)            | 18.6 (15.2–30.7) | 0.001   |
| 3-Hydroxykynurenine (nmol/L)| 52.0 (40.5–61.1)| 30.7 (26.7–37.2)            | 30.7 (22.9–37.9) | < 0.001 |
| Xanthurenic acid (nmol/L)| 13.3 (9.93–20.7)| 3.35 (2.62–6.00)            | 5.09 (3.13–8.19) | < 0.001 |
| 3-Hydroxyanthranilic acid (nmol/L)| 38.8 (29.6–50.3)| 15.3 (13.5–19.7)            | 18.4 (14.6–25.1) | < 0.001 |
| Quinolinic acid (nmol/L)| 460 (368–578)    | 314 (265–368)               | 285 (248–356)  | < 0.001 |

B-vitamins

|                      | Inclusion (nmol/L) | Time after surgery (months) | p-value |
|----------------------|--------------------|-----------------------------|---------|
|                      | 29.9 (21.8–50.2)   | 33.0 (15.8–56.1)            | 43.4 (31.3–70.3) | 0.006   |
| Riboflavin (B2) (nmol/L) | 20.5 (14.4–31.1)  | 14.5 (8.84–25.7)            | 23.1 (16.6–26.5) | 0.002   |
| Nicotinamide (B3) (nmol/L)| 295 (211–368)     | 207 (155–255)               | 219 (166–272)   | 0.002   |
| N1-methylnicotinamide (B3) (nmol/L)| 152 (104–189)| 74.0 (49.7–104)             | 119 (81.1–219)  | < 0.001 |

Values are given as median (25th to 75th percentile). P-values are based on mixed models, adjusted for type of surgery and vitamin B supplementation.

https://doi.org/10.1371/journal.pone.0192169.t004
significantly different from inclusion. Similarly, riboflavin (vitamin B2) decreased at three
months, but levels one year after surgery were not significantly different from the levels at
inclusion. The PLP-dependent ratios between 3-hydroxykynurenine:xanthurenic acid, 3-hydro-
xykynurenine:3-hydroxyanthranilic acid and 3-hydroxykynurenine:kynurenic acid were all
increased at three months after surgery, but decreased significantly after 12 months compared
to 3 months.

In order to examine whether baseline metabolite levels could predict surgical outcomes, we
analysed whether BMI, HbA1c, fasting glucose, and the TG:HDL-ratio after surgery were
related to plasma kynurenines, inflammatory markers and B vitamins at baseline. Changes in
BMI one year after surgery did not correlate with the metabolite levels at baseline, but we
observed a positive association with changes in tryptophan (p = 0.07) and kynurenine
(p = 0.014). Changes in HbA1c one year after surgery were positively correlated with baseline
levels of 3-hydroxyanthranilic acid (p = 0.041) and tryptophan (p = 0.027). In addition,
changes in 3-hydroxykynurenine one year after surgery were positively correlated to the
changes in both HbA1c (p = 0.029) and the TG:HDL-ratio (p = 0.024). The analyses were
adjusted for age, gender, eGFR, and operation method.

Discussion

In the present study we observed a positive correlation between HbA1c and both 3-hydroxyky-
urenine and 3-hydroxyanthranilic acid at baseline. One year after bariatric surgery plasma
levels of most kynurenine pathway metabolites were substantially decreased. In accordance
with previous studies weight loss was accompanied by reduced CRP and KTR, as well as
increased vitamin B6-levels. The beneficial metabolic effects one year after bariatric surgery
also included decreased levels of HbA1c, triglycerides, and remission of T2D in a high propor-
tion of patients [3, 24–26].

The role of the kynurenine pathway in obesity and during weight loss has been ambiguous.
In accordance with our study, a recent report on patients undergoing either gastric banding or
Roux-en-Y gastric bypass showed a decrease in tryptophan and kynurenine metabolites one
year after surgery [27]. However, others have shown that in patients undergoing gastric band-
ing levels of KTR and neopterin were unchanged two years after surgery [24]. In addition to
the difference in follow-up time, a possible explanation for these contrarieties may lie in the different procedures of bariatric surgery performed. Gastric banding is shown to be a less effective method on long-term outcomes compared to LGS or BPD-DS [28], which were applied in the present study.

After LSG and BPD-DS, food intake is restricted due to reduction of the gastric volume. In patients undergoing BPD-DS the uptake of nutrients is also reduced since a part of the small bowel has been bypassed. In this study bariatric surgery was followed by a decrease in plasma tryptophan, kynurenine and all the kynurenine metabolites, except for antrahlic acid. The reduction was most prominent at three months after surgery, while levels seemed to be stable between three months and one year after surgery. Since circulating levels of tryptophan and kynurenines generally are positively related [29], the observed changes might be related to restricted food intake and decreased absorption of nutrients like tryptophan, especially during the first months after surgery. Both KTR and CRP decreased after weight loss, indicating decreased inflammation. Changes in these inflammatory markers after surgery were more prominent between three and twelve months than between baseline and three months.

IFN-γ stimulates the production of neopterin by macrophages and also increases the conversion of tryptophan to kynurenine through increased activity of IDO. We observed a decrease in KTR, though levels of neopterin did not change significantly after weight loss. This might indicate that mechanisms beyond IFN-γ activity contribute to the regulation of tryptophan to kynurenine conversion in patients with obesity. The metabolism of tryptophan to kynurenine is also catalyzed by TDO, which is induced by stress hormones, such as cortisol [11]. Patients with severe obesity and metabolic impairment have increased levels of cortisol [30]. Thus, a decrease in obesity-related cortisol and TDO activation might contribute to the observed reduction in KTR after weight loss.

Low levels of PLP are linked to conditions associated with inflammation, such as CVD and metabolic syndrome [31, 32], but the mechanisms by which PLP is decreased are not fully understood. Increased inflammation seems to be associated with higher cellular uptake and catabolism of vitamin B6 [33]. Enhanced demand of PLP as a cofactor might lead to functional deficiency [34]. Additionally, stress might cause PLP deficiency by activation of the PLP phosphatase due to increased levels of cortisol [35]. Thus, an increase in vitamin B6 status after bariatric surgery as seen in our study might reflect reduced inflammation. The increase was higher between three months and one year after surgery than between baseline and three months. The decrease in the ratios between 3-hydroxykynurenine: xanturenic acid, 3-hydroxykynurenine:3-hydroxyxanthanilic acid and 3-hydroxykynurenine: kynurenic acid between three months and one year after surgery might be related to the increased PLP.

Circulating levels of the vitamin B3 complex nicotinamide and N^1^-methylnicotinamide decreased during the first three months after surgery, despite supplementation of vitamin B3. Vitamin B3 is obtained directly from the diet or synthesized from dietary tryptophan [36]. The observed decrease in vitamin B3 is possibly caused by restricted food uptake after bariatric surgery, as also reflected by lower levels of tryptophan.

At baseline the kynurenine metabolites 3-hydroxykynurenine and 3-hydroxyxanthanilic acid were positively correlated with HbA1c. Circulating concentrations of both these tryptophan metabolites decreased significantly after weight loss. In addition, changes in 3-hydroxykynurenine one year after bariatric surgery were positively correlated to changes in HbA1c and the TG:HDL-ratio. The formation of 3-hydroxykynurenine is dependent on the enzyme kynurenine 3-monooxygenase (KMO), which converts kynurenine to 3-hydroxy-L-kynurenine. KMO is present in macrophages in adipose tissue and it has been shown that KMO activity is positively correlated to HbA1c levels [37]. Additionally, elevated circulating levels of 3-hydroxykynurenine were shown in diabetic individuals with retinopathy [38]. Patients who
were operated using BPD-DS had higher incidence of T2D than the patients operated with LGS and at baseline these patients also had higher levels of 3-hydroxyanthranilic acid. 3-Hydroxyanthranilic acid is a downstream metabolite of 3-hydroxykynurenine, dependent on the enzyme kynureninase. Possibly, understanding the role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid could help elucidate why some individuals with obesity have an increased risk of developing metabolic impairment compared to metabolically healthy individuals with obesity.

Anthranilic acid was the only kynurenine metabolite measured that increased after weight loss. A different regulation of anthranilic acid compared to other kynurenines measured in individuals with obesity has previously been described [29]. Conversion of kynurenine into anthranilic acid is catalysed by the PLP-dependent enzyme kynureninase [11], and anthranilic acid increases in response to pyridoxine supplementation [39]. The increase in circulating PLP after weight loss might explain some of the observed increase in anthranilic acid. Possibly, also a reduction in the KMO activity after weight loss may favour the formation of anthranilic acid instead of 3-hydroxykynurenine. Further studies on the role of anthranilic acid in inflammatory conditions are needed.

It should be noted that patients in this study received multi-vitamin supplements containing vitamin B2, B3 and B6 after surgery. This makes it difficult to evaluate the effect of reduced inflammation vs. supplements or impaired vitamin uptake on measured levels of vitamin B3 and B6. Although, supplementation of pyridoxine does not normalize the circulating levels of inflammatory markers [40], vitamin intake was adjusted for in our analysis. Additionally, the major changes in B-vitamin levels and reduction in inflammatory markers occurred between 3 months and one year after surgery, which might indicate that the increase in B vitamins were not mainly caused by increased intake through supplements, but rather the metabolic and inflammatory changes occurring during weight loss. Two different types of bariatric surgery were used in this study, LSG and BPD-DS. The type of bariatric surgery performed possibly plays a role regarding weight loss, metabolic improvement and decreased inflammation. Due to the small sample size the present study was not designed to evaluate differences in the surgical procedures.

**Conclusion**

In summary, strong correlations between HbA1c and the kynurenine metabolites 3-hydroxykynurenine and 3-hydroxyanthranilic acid were observed in patients with obesity scheduled for bariatric surgery. Following surgery, vitamin B6 levels increased whereas KTR and CRP decreased, indicating down-regulated inflammation after profound weight loss. The role of kynurenine metabolites in the pathophysiologic pathways leading to metabolic impairment in individuals with obesity needs further evaluation.

**Supporting information**

S1 Appendix. Data file.

(XLSX)

**Acknowledgments**

The study was supported by the West Norway Regional Health Authority.

**Author Contributions**

**Conceptualization:** Monika H. E. Christensen, Dag J. Fadnes, Eva R. Pedersen, John R. Andersen, Villy Våge, Per M. Ueland, Ottar K. Nygård, Gunnar Mellgren.
Data curation: Monika H. E. Christensen, Dag J. Fadnes, Therese H. Røst, Eva R. Pedersen, John R. Andersen, Villy Våge, Ottar K. Nygård, Gunnar Mellgren.

Formal analysis: Monika H. E. Christensen, Dag J. Fadnes, Therese H. Røst, Eva R. Pedersen, Arve Ulvik, Øivind Midttun, Per M. Ueland.

Funding acquisition: John R. Andersen, Villy Våge, Ottar K. Nygård, Gunnar Mellgren.

Investigation: Monika H. E. Christensen, Dag J. Fadnes, Therese H. Røst, Eva R. Pedersen, John R. Andersen, Ottar K. Nygård, Gunnar Mellgren.

Methodology: Monika H. E. Christensen, Dag J. Fadnes, Therese H. Røst, Eva R. Pedersen, John R. Andersen, Arve Ulvik, Øivind Midttun, Per M. Ueland, Ottar K. Nygård, Gunnar Mellgren.

Project administration: Monika H. E. Christensen, John R. Andersen.

Resources: Monika H. E. Christensen, Dag J. Fadnes.

Supervision: Ottar K. Nygård, Gunnar Mellgren.

Validation: Monika H. E. Christensen, Eva R. Pedersen, John R. Andersen, Ottar K. Nygård, Gunnar Mellgren.

Writing – original draft: Monika H. E. Christensen, Dag J. Fadnes, Therese H. Røst, Eva R. Pedersen.

Writing – review & editing: Monika H. E. Christensen, Eva R. Pedersen, John R. Andersen, Villy Våge, Arve Ulvik, Øivind Midttun, Per M. Ueland, Ottar K. Nygård, Gunnar Mellgren.

References

1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377(9765):557–67. Epub 2011/02/08. https://doi.org/10.1016/S0140-6736(10)62037-5 PMID: 21295846.

2. Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373(9669):1083–96. Epub 2009/03/21. https://doi.org/10.1016/S0140-6736(09)60318-4 PMID: 19299006; PubMed Central PMCID: PMC2662372.

3. Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014; 311(22):2297–304. Epub 2014/06/11. https://doi.org/10.1001/jama.2014.5988 PMID: 24915261.

4. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al. Bariatric surgery versus nonsurgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013; 347:f5934. Epub 2013/10/24. https://doi.org/10.1136/bmj.f5934 PMID: 24149519; PubMed Central PMCID: PMC3806364.

5. Grant RW, Stephens JM. Fat in flames: Influence of cytokines and pattern recognition receptors on adipocyte lipolysis. Am J Physiol Endocrinol Metab. 2015;ajpendo 00053 2015. Epub 2015/06/11. https://doi.org/10.1152/ajpendo.00053.2015 PMID: 26058883.

6. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004; 53 Suppl 1:S143–51. Epub 2004/01/30. PMID: 14749280.

7. Cancello R, Henegar C, Viguier N, Taleb S, Poitou C, Rouault C, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005; 54(8):2277–86. Epub 2005/07/28. PMID: 16046292.
8. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014; 105(2):141–50. Epub 2014/05/07. https://doi.org/10.1016/j.diabres.2014.04.006 PMID: 24798950.

9. Wensveen FM, Jelenic V, Valentis S, Sestan M, Wensveen TT, Theurich S, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol. 2015; 16(4):376–85. Epub 2015/03/03. https://doi.org/10.1038/ni.3120 PMID: 25729921.

10. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014; 41(1):36–48. Epub 2014/07/19. https://doi.org/10.1016/j.immuni.2014.05.010 PMID: 25035952.

11. Schwarz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nature reviews Neuroscience. 2012; 13(7):465–77. Epub 2012/06/09. https://doi.org/10.1038/nrn3257 PMID: 22678511; PubMed Central PMCID: PMC3681811.

12. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003; 81(4):247–65. Epub 2003/07/10. https://doi.org/10.1046/j.1440-1711.2003.t01-1-01177.x PMID: 12848846.

13. Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem. 1996; 66(3):996–1004. Epub 1996/03/01. PMID: 8769859.

14. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002; 3(2):175–87. Epub 2002/05/11. PMID: 12003349.

15. Huber C, Batchelor JR, Fuchs D, Hausen A, Niederwieser D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984; 160(1):310–6. Epub 1984/07/01. PMID: 6429267; PubMed Central PMCID: PMC2187425.

16. Mandi Y, Vecsei L. The kynurenine system and immunoregulation. Journal of neural transmission. 2012; 119(2):197–209. Epub 2011/12/07. https://doi.org/10.1007/s00702-011-0681-y PMID: 21744051.

17. Oxenkrug GF. Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders. J Neural Transm. 2011; 118(1):75–85. Epub 2010/09/03. https://doi.org/10.1007/s00702-010-0475-7 PMID: 20811799; PubMed Central PMCID: PMC3026891.

18. Brandacher G, Winkler C, Aigner F, Schweibberger H, Schroecksnadel K, Margreiter R, et al. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obes Surg. 2006; 16(5):541–8. Epub 2006/05/12. https://doi.org/10.1381/096089206776945066 PMID: 16687019.

19. Rojano-Rodriguez ME, Valenzuela-Salazar C, Cardenas-Lailson LE, Romero Loera LS, Torres-Olalde M, Moreno-Portillo M. C-reactive protein level in morbidly obese patients before and after bariatric surgery. Revista de gastroenterologia de Mexico. 2014; 79(2):90–5. Epub 2014/06/01. https://doi.org/10.1016/j.rjgmx.2013.11.002 PMID: 24878218.
26. Aasheim ET, Bjorkman S, Sovik TT, Engstrom M, Hanvold SE, Maia T, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr. 2009; 90(1):15–22. Epub 2009/05/15. https://doi.org/10.3945/ajcn.2009.27583 PMID: 19439456.

27. Favennec M, Hennart B, Verbanck M, Pigeyre M, Caiazzo R, Raverey V, et al. Post-Bariatric Surgery Changes in Quinolinic and Xanthurenic Acid Concentrations Are Associated with Glucose Homeostasis. PLoS One. 2016; 11(6):e0158051. Epub 2016/06/22. https://doi.org/10.1371/journal.pone.0158051 PMID: 27327770; PubMed Central PMCID: PMC4915629.

28. Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg. 2007; 17(9):1248–56. Epub 2007/12/13. PMID: 18074502.

29. Theofylaktopoulos D, Midttun O, Ulvik A, Ueland PM, Tell GS, Vollset SE, et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013; 173(1):121–30. Epub 2013/04/24. https://doi.org/10.1111/cei.12092 PMID: 23607723; PubMed Central PMCID: PMC3694542.

30. Constantinopoulou P, Michalaki M, Kottorou A, Habeos I, Payrogianis F, et al. Cortisol in tissue and systemic level as a contributing factor to the development of metabolic syndrome in severely obese patients. Eur J Endocrinol. 2015; 172(1):69–78. Epub 2014/10/23. https://doi.org/10.1530/EJE-14-0626 PMID: 25336506.

31. Cheng CH, Lin PT, Liaw YP, Ho CC, Tsai TP, Chou MC, et al. Plasma pyridoxal 5'-phosphate and high-sensitivity C-reactive protein are independently associated with an increased risk of coronary artery disease. Nutrition. 2008; 24(3):239–44. Epub 2008/03/04. doi: S0899-9007(07)00358-9 [pii] https://doi.org/10.1016/j.nut.2007.12.003 PMID: 18312786.

32. Shen J, Lai CQ, Mattei J, Ordovas JM, Tucker KL. Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study. Am J Clin Nutr. 2010; 91(2):337–42. Epub 2009/12/04. doi: ajcn.2009.28571 [pii] https://doi.org/10.3945/ajcn.2009.28571 PMID: 19955400; PubMed Central PMCID: PMC2806890.

33. Ulvik A, Midttun O, Ringdal Pedersen E, Nygard O, Ueland PM. Association of plasma B-6 vitamers with systemic markers of inflammation before and after pyridoxine treatment in patients with stable angina pectoris. Am J Clin Nutr. 2012. Epub 2012/04/12. doi: ajcn.111.029751 [pii] https://doi.org/10.3945/ajc.111.029751 PMID: 2292365.

34. Paul L, Ueland PM, Selhub J. Mechanistic perspective on the relationship between pyridoxal 5'-phosphate and inflammation. Nutr Rev. 2013; 71(4):239–44. Epub 2013/04/05. https://doi.org/10.1111/nure.12014 PMID: 23550784.

35. Mahuren JD, Dubeski PL, Cook NJ, Schaefer AL, Coburn SP. Adrenocorticotrophic hormone increases hydrolysis of B-6 vitamers in swine adrenal glands. J Nutr. 1999; 129(10):1905–8. Epub 1999/09/28. PMID: 10498766.

36. Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. International journal of dermatology. 2004; 43(1):1–5. Epub 2003/12/25. PMID: 14693013.

37. Favennec M, Hennart B, Caiazzo R, Leloir A, Yengo L, Verbanck M, et al. The kynurenine pathway is activated in human obesity and shifted toward kynurenine monoxygenase activation. Obesity (Silver Spring). 2015; 23(10):2066–74. Epub 2015/09/09. https://doi.org/10.1002/oby.2199 PMID: 26347385.

38. Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Archives of physiology and biochemistry. 2011; 117(5):254–8. Epub 2011/11/01. https://doi.org/10.3109/13813455.2011.623705 PMID: 22034910.

39. Midttun O, Ulvik A, Ringdal Pedersen E, Ebbing M, Bleie O, Schartum-Hansen H, et al. Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr. 2011; 141(4):611–7. Epub 2011/02/12. doi: jn.110.133082 [pii] https://doi.org/10.3945/jn.110.133082 PMID: 21310866.

40. Lotto V, Choi SW, Friso S. Vitamin B6: a challenging link between nutrition and inflammation in CVD. Br J Nutr. 2011; 1–13. Epub 2011/04/14. doi: S0007114511000407 [pii] https://doi.org/10.1017/S0007114511000407 PMID: 21486513.